To Evaluate the Effectiveness of Plasmapheresis as a Method for the Graft Disease Prevention in Patients with Keratoplasty
Open Access
- 29 December 2021
- journal article
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 18 (4), 946-954
- https://doi.org/10.18008/1816-5095-2021-4-946-954
Abstract
Purpose: to evaluate the effectiveness of plasmapheresis as a method for preventing and treating the graft rejection reaction in corneal transplantation.Patients and methods. The study involved patients with surgical pathology of the cornea, who underwent a prophylactic course of plasmapheresis procedures and underwent penetrating keratoplasty (Main group); and patients with surgical pathology of the cornea who underwent penetrating keratoplasty, but did not undergo plasmapheresis (Comparison group), whose data were analyzed retrospectively. The control group consisted of conditionally healthy individuals of both genders. Subgroups of patients with high and low risk keratoplasty were also identified within the Main group and the Comparison group.Results. Patients with keratoplasty who received a course of therapeutic plasmapheresis in the perioperative period demonstrated a statistically significant increase in the number of cases of a decrease in the level of C-reactive protein and a statistically significant decrease in the median values of the mean stimulated cytochemical index and the mobilization coefficient. Depending on the risk group for keratoplasty, the patients showed different dynamics of the levels of the studied interleukins after the course of plasmapheresis and keratoplasty. In patients of the Comparison group who did not receive a course of plasmapheresis in the preoperative period, over a period of 1.3 years, 22 cases (24 %) developed graft disease, while patients of both subgroups of the Main group who received a course of therapeutic plasmapheresis in the preoperative period, didn’t demonstrate any cases of graft disease. In patients of the Comparison group (in total for two subgroups), the maximum number of cases of graft disease (n = 24) was observed in the first 500 days after surgery. At the same time, the patients of the Main group who underwent plasmapheresis had the best graft survival rates: during the observation period, there were no cases of graft disease (in both subgroups).Conclusion: the obtained data indicate the ability of plasmapheresis, performed in the perioperative period, to prevent the development of graft disease in patients with keratoplasty.Keywords
This publication has 16 references indexed in Scilit:
- A Method for Developing Novel 3D Cornea-on-a-Chip Using Primary Murine Corneal Epithelial and Endothelial CellsFrontiers in Pharmacology, 2020
- Immunology of acute phase proteins of inflammation and work of R.V. PetrovImmunologiya, 2020
- Role of plasmapheresis in neuromyelitis optica spectrum disordersPublished by KIMS Foundation and Research Center ,2019
- 3D bioprinting for artificial cornea: Challenges and perspectivesMedical Engineering & Physics, 2019
- Immune privilege in corneal transplantationProgress in Retinal and Eye Research, 2019
- Risk factors for graft failure after penetrating keratoplastyMedicine, 2019
- RESTORATION OF CORNEA ENDOTHELIUM FUNCTION (review)Siberian Scientific Medical Journal, 2019
- Plasmapheresis Therapy in Kidney Transplant RejectionBlood Purification, 2018
- Risk factors, clinical presentations, prevention, and treatment of corneal graft rejectionVestnik oftal'mologii, 2016
- ABO antigen blood-group compatibility and allograft rejection in corneal transplantationActa Ophthalmologica Scandinavica, 1999